https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-08-01 / Zhonghua Nan Ke Xue 2010 Aug;16(8):698-704
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-08-01 / Zhonghua Nan Ke Xue 2010 Aug;16(8):698-7042010-08-01 00:00:002019-02-15 08:52:54[Auto-dendritic cell vaccines pulsed with PSA, PSMA and PAP peptides for hormone-refractory prostate cancer]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-05-01 / Curr Opin Urol 2010 May;20(3):241-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-05-01 / Curr Opin Urol 2010 May;20(3):241-62010-05-01 00:00:002019-02-15 08:53:01Current status of immunological therapies for prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-04-28 / J. Immunol. 2010 Jun;184(11):5954-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-04-28 / J. Immunol. 2010 Jun;184(11):5954-82010-04-28 00:00:002019-02-15 08:52:59Cutting edge: delay and reversal of T cell tolerance by intratumoral injection of antigen-loaded dendritic cells in an autochthonous tumor model
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-12-01 / Cancer Treat. Rev. 2010 Apr;36(2):131-41
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-12-01 / Cancer Treat. Rev. 2010 Apr;36(2):131-412009-12-01 00:00:002019-02-15 08:53:00The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-12-01 / Expert Opin Biol Ther 2009 Dec;9(12):1565-75
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-12-01 / Expert Opin Biol Ther 2009 Dec;9(12):1565-752009-12-01 00:00:002019-02-15 09:23:56A changing world for DCvax: a PSMA loaded autologous dendritic cell vaccine for prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-10-13 / Int. J. Urol. 2010 Jan;17(1):20-30
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-10-13 / Int. J. Urol. 2010 Jan;17(1):20-302009-10-13 00:00:002009-10-13 00:00:00Oncolytic virus therapy for prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-06-15 / Prostate 2009 Jun;69(9):938-48
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-06-15 / Prostate 2009 Jun;69(9):938-482009-06-15 00:00:002019-02-15 08:53:14Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-05-01 / Prostate 2009 May;69(6):571-84
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-05-01 / Prostate 2009 May;69(6):571-842009-05-01 00:00:002019-02-15 08:53:02Androgen ablation augments prostate cancer vaccine immunogenicity only when applied after immunization
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-04-11 / Urol. Oncol. 2010 May-Jun;28(3):290-5
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-04-11 / Urol. Oncol. 2010 May-Jun;28(3):290-52009-04-11 00:00:002019-02-15 08:53:01Tumor specific cytotoxicity and telomerase down-regulation in prostate cancer by autologous dendritic cells loaded with whole tumor cell antigens
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2009-03-01 / Future Oncol 2009 Mar;5(2):187-96
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2009-03-01 / Future Oncol 2009 Mar;5(2):187-962009-03-01 00:00:002019-02-15 09:23:58Promising novel immunotherapies and combinations for prostate cancer
